Multiple Myeloma
- 5 June 1997
- journal article
- review article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 336 (23) , 1657-1664
- https://doi.org/10.1056/nejm199706053362307
Abstract
Multiple myeloma is a disorder in which malignant plasma cells accumulate in the bone marrow and produce an immunoglobulin, usually monoclonal IgG or IgA. Common complications of overt multiple myeloma include recurrent bacterial infections, anemia, osteolytic lesions, and renal insufficiency. Multiple myeloma is responsible for about 1 percent of all cancer-related deaths in Western countries. Its epidemiologic pattern remains obscure, and its cause is unknown.1 Monoclonal Gammopathy of Undetermined Significance and the Natural History of Multiple MyelomaA monoclonal gammopathy of undetermined significance is marked by the presence in the serum of monoclonal IgG or IgA without evidence of multiple . . .Keywords
This publication has 66 references indexed in Scilit:
- Effect of interferon on the health‐related quality of life of multiple myeloma patients: results of a Nordic randomized trial comparing melphalan–prednisone to melphalan–prednisone + α‐interferonBritish Journal of Haematology, 1996
- A comparison of polychemotherapy and melphalan/prednisone for primary remission induction, and interferon-alpha for maintenance treatment, in multiple myeloma. A prospective trial of the German Myeloma Treatment GroupEuropean Journal Of Cancer, 1995
- Interferon alfa‐2b versus no maintenance therapy during the plateau phase in multiple myeloma: a randomized studyBritish Journal of Haematology, 1995
- Modulation of multidrug-resistant multiple myeloma by cyclosporinThe Lancet, 1992
- Alpha‐2a‐interferon/melphalan/prednisone versus melphalan/prednisone in previously untreated patients with multiple myelomaBritish Journal of Haematology, 1990
- Maintenance Treatment with Recombinant Interferon Alfa-2b in Patients with Multiple Myeloma Responding to Conventional Induction ChemotherapyNew England Journal of Medicine, 1990
- The role of interleukin‐1 and tumour necrosis factor‐α in human multiple myelomaBritish Journal of Haematology, 1990
- Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomasNature, 1988
- Prognostic factors in multiple myelomaCancer, 1975
- PART I. ANALYSIS OF PRESENTING FEATURES OF PROGNOSTIC IMPORTANCEBritish Journal of Haematology, 1973